Psychedelic Stock Gainers And Losers From January 18, 2022
GAINERS:
Cybin (AMEX:CYBN) shares closed up 1.90% at $1.07
MindMed Launches Study Using Monitoring System For Psychedelic Experiences
Psychedelics biotech company MindMed (NASDAQ: MNMD) has enrolled the first subjects into its Session Monitoring System study.
The company’s Session Monitoring System is a technology platform that can collect sensory data during a therapy session with a psychedelic drug.
Psyched: Canada’s Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington
Canada Opens New Legal Pathways For Access To Treatment With Psilocybin And MDMA
MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine
On Tuesday, Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) reported the completion of its Phase 1 clinical trial of 18-MC, the company’s non-hallucinogenic proprietary derivative of ibogaine, being developed for the treatment of indications linked to opioid use d
Cannabis Movers & Shakers: MindMed & Trulieve Management Shake-Ups, Credex Corp & CapStone Bolster Leadership Teams
MindMed Announces Management Shake-Ups
Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a psychedelic-based biotech company, announced Wednesday that Bradford Cross, its chief technology officer, has transitioned from his role.
‘Another Washington City Moves To Decriminalize Psychedelics, With Unanimous Council Vote’ -Marijuana Moment Report
https://www.marijuanamoment.net/another-washington-city-moves-to-decriminalize-psychedelics-with-unanimous-council-vote/
‘Activists File Colorado Ballot Initiatives To Legalize Psychedelics And Establish ‘Healing Center’ Program’ -Marijuana Moment Report
https://www.marijuanamoment.net/activists-file-colorado-ballot-initiatives-to-legalize-psychedelics-and-establish-healing-center-program/
MindMed Advances Phase 2a LSD Microdose Trial For Adult ADHD
Neuro-pharmaceutical and psychedelics company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced Friday the initiation of Phase 2a proof-of-concept trial of LSD (lysergic acid diethylamide) in adult patients with attention deficit hyperactivity disorder.
‘Congressman Asks Colleagues To Demand DEA Allow Psilocybin Treatment For Terminal Patients’ -Marijuana Moment Report
https://www.marijuanamoment.net/congressman-asks-colleagues-to-demand-dea-allow-psilocybin-treatment-for-terminal-patients/